

Supplementary Material: Central Nervous System Progression in Primary Vitreoretinal Lymphoma with Bilateral and Unilateral Involvement: A Systematic Review and Meta-Analysis

Josephus L. M. van Rooij, Klaudia A. Tokarska, Ninette H. ten Dam-van Loon, Peter H. Wessels, Tatjana Seute, Monique C. Minnema and Tom J. Snijders

Table S1. Search strategy.

Database	Search strategy	Results
Pubmed	("VRL"[tiab] OR "PVRL"[tiab] OR (("Lymphoma"[Mesh] OR "Lymphoma*"[tiab]) AND ("Eye"[Mesh] OR "Eye"[tiab] OR "Eyes"[tiab] OR "intraocular"[tiab] OR "Vitreoretinal"[tiab] OR "ocular"[tiab] OR "vitreous retinal"[tiab]))) AND ("Central Nervous System"[Mesh] OR "Central Nervous System Neoplasms"[Mesh:NoExp] OR "Brain Neoplasms"[Mesh] OR "Central Nervous System"[tiab] OR "Central nerve System"[tiab] OR "CNS"[tiab] OR "brain"[tiab] OR "cerebral"[tiab])	924
Embase	('VRL':ti,ab,kw OR 'PVRL':ti,ab,kw OR (('lymphoma'/exp OR 'Lymphoma*':ti,ab,kw) AND ('eye'/exp OR 'Eye':ti,ab,kw OR 'Eyes':ti,ab,kw OR 'intraocular':ti,ab,kw OR 'Vitreoretinal':ti,ab,kw OR 'ocular':ti,ab,kw OR 'vitreous retinal':ti,ab,kw))) AND ('central nervous system'/exp OR 'central nervous system tumor'/de OR 'brain tumor'/exp OR 'central nervous system cancer'/exp OR 'Central Nervous System':ti,ab,kw OR 'Central nerve System':ti,ab,kw OR 'CNS':ti,ab,kw OR 'brain':ti,ab,kw OR 'cerebral':ti,ab,kw) NOT ('conference abstract'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it) NOT (('animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp)	1195

Table S2. Customized QUIPS assessment form.

Biases	Issues to consider for judging
Study participation	<ol style="list-style-type: none"> 1. Source of target population 2. Method used to identify population 3. Recruitment period 4. Place of recruitment 5. Inclusion and exclusion criteria 6. Baseline characteristics 7. Timing of diagnosis (before or after CNS progression)
Study attrition	<ol style="list-style-type: none"> 1. Proportion of baseline sample available for analysis 2. Reasons and potential impact of subjects lost to follow-up 3. Outcome and prognostic factor information on lost to follow-up
Prognostic factor (PF) measurement	<ol style="list-style-type: none"> 1. Proportion of data on PF available for analysis
Outcome measurement	<ol style="list-style-type: none"> 1. Definition of the outcome 2. Valid and reliable measurement of outcome 3. Method and setting of outcome measurement
Study confounding	<ol style="list-style-type: none"> 1. Important confounders measured 2. Definition of the confounding factor 3. Appropriate accounting for confounding
Statistical analysis and reporting	<ol style="list-style-type: none"> 1. Presentation of analytical strategy 2. Reporting of results